Colmenero Castillo J D, Hernandez Marquez S, Reguera Iglesias J M, Cabrera Franquelo F, Rius Diaz F, Alonso A
Departamento Medicina Interna, Hospital Regional Carlos Haya, Malaga, Espana.
Chemotherapy. 1989;35(2):146-52. doi: 10.1159/000238662.
Effectiveness and therapeutic value of the doxycycline plus streptomycin and doxycycline plus rifampin schedules of treatment of human brucellosis have been assessed by carrying out a prospective study on 111 patients randomly distributed into two groups. Patients in group A were treated with doxycycline plus streptomycin sulphate and those in group B with doxycycline plus rifampin. The temperature of all patients reverted to normal, and 54 patients from group A (91.6%) and 45 from group B (86.5%) achieved total recovery with a single therapeutic cycle. Two therapeutic failures and 3 relapses in group A (8.4%) and 7 relapses in group B (13.46%) were observed. The tolerance to both regimens was good. Although the combination doxycycline plus rifampin offers a more convenient oral administration, in the light of these results, until more extensive research is carried out, it should be considered as an alternative rather than a first choice in the treatment of human brucellosis.
通过对111例随机分为两组的患者进行前瞻性研究，评估了强力霉素联合链霉素以及强力霉素联合利福平治疗人类布鲁氏菌病方案的有效性和治疗价值。A组患者接受强力霉素加硫酸链霉素治疗，B组患者接受强力霉素加利福平治疗。所有患者体温均恢复正常，A组54例患者（91.6%）和B组45例患者（86.5%）经单一治疗周期实现完全康复。观察到A组有2例治疗失败和3例复发（8.4%），B组有7例复发（13.46%）。两种治疗方案的耐受性均良好。尽管强力霉素加利福平联合用药口服给药更方便，但鉴于这些结果，在开展更广泛的研究之前，在人类布鲁氏菌病治疗中应将其视为一种替代方案而非首选方案。
